COMBINATION TREATMENT OF ABT-450 AND RITONAVIR AND E.G. ABT-072 AND/OR ABT-333|FOR USE IN TREATING HCV

摘要

In one aspect, the present invention features HCV therapies comprising administering to a patient in need thereof an HCV protease inhibitor (like ABT-450 (compound 1) or danoprevir) and a cytochrome P450 monooxygenase inhibitor like ritonavir or cobicistat, wherein ritonavir is used as a pharmacokinetic booster to improve the pharmacokinetics of the HCV protease inhibitor. The HCV therapies do not require the testing of total cholesterol and triglyceride levels prior to and after the therapies.